Healthcare Industry News: vascular access
News Release - October 27, 2009
AngioDynamics Appoints Stephen McGill as Senior Vice President and General Manager, InternationalQUEENSBURY, N.Y., Oct., 27--(HSMN NewsFeed)--AngioDynamics (NASDAQ:ANGO ), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today it appointed Stephen J. McGill, 47, to a newly-created position, Senior Vice President and General Manager, International. Mr. McGill’s appointment is effective November 1, 2009. He will be based in Europe and will report to Jan Keltjens, Chief Executive Officer of AngioDynamics.
“International markets represent key growth opportunities for our Company, and Stephen has the strengths and expertise to drive this very important strategic effort,” said Mr. Keltjens. “He has demonstrated strong capabilities to build and develop sales and marketing organizations for high-growth companies throughout the world. He has an in-depth knowledge of the global healthcare industry, and extensive experience in the U.S. and international markets. We believe Stephen will be instrumental in helping AngioDynamics target and expand its business in the international arena, and will make significant contributions to our growth.”
From 2000-08, Mr. McGill worked at American Medical Systems in progressively larger roles, most recently serving as Senior Vice President, Global Sales. In that position, he was a significant contributor to the Company’s 76% growth in revenue from 2005-07 and the integration of Laserscope following its acquisition. Since leaving American Medical Systems, Mr. McGill served as a Principal at AEM Global, a consulting firm specializing in developing market opportunities worldwide for medical device companies, working with clients including Tornier and Spinewave. Prior to his experience at AMS, he held increasing leadership roles with Bolton Medical, Boston Scientific, Stryker UK, Wesley Jessen (a division of Schering Plough), and Allergen. Mr. McGill attended Anniesland College in Glasgow.
“AngioDynamics is a leader in innovative medical devices that has gained an excellent reputation among physicians and hospitals, especially in the U.S.,” said Mr. McGill. “International markets represent an outstanding growth opportunity for the Company, and I am delighted to be joining AngioDynamics at this time to help drive this important initiative.”
AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company’s diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company’s expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to integrate purchased businesses as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.